Man Group
ALDX icon

Man Group’s Aldeyra Therapeutics ALDX Stock Holding History

Man Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,967
Closed -$141K – 1868
2022
Q4 		$139K Buy
+19,967
New +$114K ﹤0.01% 1847
2020
Q4 		– Sell
-14,200
Closed -$105K – 1809
2020
Q3 		$105K Buy
+14,200
New +$91.7K ﹤0.01% 1740

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Man Group's ALDX Position: Q1 2023 in Review

Man Group sold out of Aldeyra Therapeutics (ALDX) in Q1 2023, closing a stake of 19,967 shares — an estimated $141K sold.

Man Group first reported a position in ALDX in Q3 2020 and held it in 2 quarters. The position peaked at $139K in Q4 2022. 108 funds tracked by Wall St. Rank hold ALDX as of Q1 2023.

  • Man Group reported no remaining Aldeyra Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Man Group sold 19,967 Aldeyra Therapeutics shares in Q1 2023, an estimated $141K.
  • Man Group first reported a position in Aldeyra Therapeutics in Q3 2020 and held it in 2 quarters.
  • Man Group's Aldeyra Therapeutics position peaked at $139K in Q4 2022.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.